American Society of Hirudotherapy

Morganella Morganii Infection in Hirudo Medicinalis (Iran): A Case Report

Case report published in Veterinary sciences (2022)

Last Updated: November 1, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportGenomics & ProteomicsSafety & Infection ControlAntimicrobial ResistanceRahmati Holasoo H et al. · Veterinary sciences, 2022

Abstract

Medicinal leeches (Hirudo medicinalis) are used in surgical and non-surgical manners. Morganella morganii is an opportunistic and zoonotic pathogenic bacterium causing serious clinical complications. In this study, we isolated, discovered and characterized M. morganii-infected H. medicinalis. We detected and identified M. morganii in all inflamed and swollen Hirudo medicinalis samples. The 16S rRNA sequence of the isolates confirmed all strains of M. morganii. All strains were sensitive to Ceftriaxone, Ceftiofur, Danofloxacin, Ciprofloxacin, Enrofloxacin, Oxytetracycline, and Meropenem and were resistant to Erythromycin, Amoxicillin, Ampicillin, Cefazolin, Colistin, Penicillin G, and Lincomycin. This pathogenic bacterium is a zoonotic pathogen, and monitoring the prevalence rate of this bacteria is strongly necessary for leeches used in human medical treatment and care. Finally, all infected leeches were treated successfully in this case report study.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Summary

This case report isolates Morganella morganii from inflamed Hirudo medicinalis in Iran, confirms identity by 16S rRNA sequencing, and reports susceptibility to antibiotics including ciprofloxacin and enrofloxacin but resistance to erythromycin, amoxicillin, penicillin G, and colistin.

Why This Matters for Hirudotherapy

This report examined the isolation and characterization of Morganella morganii — an opportunistic, zoonotic pathogenic bacterium — from inflamed and swollen medicinal leech (Hirudo medicinalis) specimens, including 16S rRNA confirmation and antibiotic susceptibility profiling of the isolates. M. morganii can cause serious clinical complications, and the reported resistance profile (resistant to ampicillin, penicillin G, amoxicillin, and others; sensitive to ciprofloxacin, meropenem, and several additional agents) informs microbial safety considerations for leeches used in human medical treatment. The authors emphasize that monitoring prevalence of this pathogen in therapeutic leeches is necessary, and note that all infected leeches were treated successfully. This is a case report providing no quantitative prevalence data, no human clinical outcome data, and no broader surveillance.

Citation

Reference (Vancouver style)

Rahmati Holasoo H, Tamai IA, Brück WM, Pakbin B, Nasiri A, Azizi A. Morganella Morganii Infection in Hirudo Medicinalis (Iran): A Case Report. Vet Sci. 2022;9(10):562. doi:10.3390/vetsci9100562. PMID: 36288175

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.